<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M430</article-id>
      <article-id pub-id-type="publisher-id">molbank-2005-M430</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>N-{(2<italic>Z</italic>)-4-[4-(3-chlorophenyl)piperazin-1-yl]but-2-enyl}-1,8-naphthalimide</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kowalska</surname>
            <given-names>Teresa</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kowalski</surname>
            <given-names>Piotr</given-names>
          </name>
          <xref rid="c1-molbank-2005-M430" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2005-M430">Institute of Organic Chemistry and Technology, Cracow University of Technology, 24 Warszawska Str., 31-155 Krak&#xF3;w, Poland.</aff>
      <author-notes>
        <corresp id="c1-molbank-2005-M430">Phone (+4812)-628-27-22, e-mail: <email>kowapi@usk.pk.edu.pl</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>08</month>
        <year>2005</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>09</month>
        <year>2005</year>
      </pub-date>
      <volume>2005</volume>
      <issue>3</issue>
      <elocation-id>M430</elocation-id>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>07</month>
          <year>2004</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>07</month>
          <year>2004</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2005 MDPI.</copyright-statement>
        <copyright-year>2005</copyright-year>
        <license>
          <p>All rights reserved.</p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>arylpiperazines</kwd>
		<kwd>serotonin receptors ligands</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>In continuation of our interest on synthesis and properties of arylpiperazine derivatives investigated as a serotonin receptors ligands [<xref ref-type="bibr" rid="B1-molbank-2005-M430">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2005-M430">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2005-M430">3</xref>], herein we presented one-pot synthesis of N-{(2<italic>Z</italic>)-4-[4-(3-chlorophenyl)piperazin-1-yl]but-2-enyl}-1,8-naphthalimide (<bold>4</bold>). Starting materials e.g. 1,8-naphthalimide (<bold>1</bold>), (<italic>Z</italic>)-1,4-dichloro-2-butene (<bold>2</bold>), and 1-(3-chlorophenyl)piperazine hydrochloride (<bold>3</bold>) were commercially available reagents.</p>
        <p><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2005-M430-i001.tif"/>
      </p>
      <p>A mixture of the 1,8-naphthalimide (<bold>1</bold>) (3.94 g, 0.02 mole), powdered K<sub>2</sub>CO<sub>3</sub> (4.14 g, 0.03 mole), catalytic amount of KI, and 40 mL of DMF was stirred at ambient temperature for 2 h. Than the (<italic>Z)</italic>-1,4-dichloro-2-butene (<bold>2</bold>) (2.50 g, 0.02 mole) was added and the stirring continued for another 10 h. Next, a new portion of anhydrous K<sub>2</sub>CO<sub>3</sub> (5.25 g, 0.04 mole) and 1-(3-chlorophenyl)piperazine hydrochloride (<bold>3</bold>) (4.66 g, 0.02 mole) was added and the reaction mixture was stirred again for 10 h. The mixture was filtrated and the filtrate evaporated. The residue was suspended in 50 mL of acetone, which was decanted from semisolids, and the procedure repeated to give solid crystals. This material purified by crystallization with 1-butanol afforded of the desired N-{(2<italic>Z</italic>)-4-[4-(3-chlorophenyl)piperazin-1-yl]but-2-enyl}-1,8-naphthalimide (<bold>4</bold>) (3.1 g, 35%) as the light yellow crystals. For biological experiments the base <bold>4</bold> was converted into hydrochloride salt with ethanol saturated with HCl. </p>
      <p>Melting point: 138&#x2013;140 &#xB0;C. (for HCl salt mp 279&#x2013;281 &#xB0;C)</p>
      <p><sup>1</sup>H-NMR (80 MHz, CDCl<sub>3</sub>): &#x3B4;= 2.64&#x2013;2.76 (m, 4H, 2CH<sub>2</sub>-pip); 3.17&#x2013;3.30 (m, 4H, 2CH<sub>2</sub>-pip); 3.39 (d, 2H, CH<sub>2</sub>-N-pip); 4.87 (d, 2H, CH<sub>2</sub>-N-imide); 5.68&#x2013;5.79 (m, 2H, CH=CH); 6.74&#x2013;7.26 (m, 4H, ArH); 7.74 (t, 2H, H<sub>3,6</sub>-imide); 8.22 (d, 2H, H<sub>4,5</sub>-imide); 8.61(d, 2H, H<sub>2,7</sub>-imide).</p>
      <p>IR (KBr, cm<sup>-1</sup>): 2954-2780 (CH); 1699, 1663 (C=O); 1590-1435 (C=C).</p>
      <p>MS (EI, 70 eV; m/z, rel.%): 445 [M<sup>+</sup>] (21); 250 (61); 235 (100); 196 (15); 180 (32).</p>
      <p>Elemental Analysis: Calculated for C<sub>26</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub>.HCl (482.41): C, 64.73%; H, 5.22%; N, 8.71%. Found: C, 64.79%; H, 5.33%; N, 8.48%.</p>
  </body>
  <back>
  <app-group>
    <app id="app1-molbank-2005-M430">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2005-M430-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2005-M430-s001-mod.mol">
       <label>Supplementary File 1</label>
        </supplementary-material>
        <supplementary-material id="molbank-2005-M430-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2005-M430-s001.mol">
        <label>Supplementary File 2</label>
       </supplementary-material>
     </app>
 </app-group>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2005-M430">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kowalski</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mokrosz</surname>
              <given-names>M. J.</given-names>
            </name>
            <name>
              <surname>Majka</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Kowalska</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Duszy&#x144;ska</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <source>J. Heterocyclic Chem.</source>
          <year>2000</year>
          <volume>37</volume>
          <fpage>187</fpage>
          <lpage>189</lpage>
        </citation>
      </ref>
      <ref id="B2-molbank-2005-M430">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kowalski</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kowalska</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mokrosz</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Bojarski</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Charakchieva-Minol</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <source>Molecules</source>
          <year>2001</year>
          <volume>6</volume>
          <fpage>784</fpage>
          <lpage>795</lpage>
        </citation>
      </ref>
      <ref id="B3-molbank-2005-M430">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bojarski</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Kowalski</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kowalska</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Duszy&#x144;ska</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Charakchieva-Minol</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tatarczy&#x144;ska</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>K&#x142;odzi&#x144;ska</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chojnacka-W&#xF3;jcik</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem.</source>
          <year>2002</year>
          <volume>10</volume>
          <fpage>3817</fpage>
          <lpage>3827</lpage>
          <pub-id pub-id-type="pmid">12413835</pub-id>
        </citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p><italic>Sample Availability</italic>: Available from MDPI.</p>
      </fn>
    </fn-group>
  </back>
</article>
